NCT07060365 2026-04-03
A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer
AstraZeneca
Phase 1/2 Withdrawn
Clinical Trials
16 trialsNCT07211204 2026-03-03
Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population
Timser SAPI de CV
Phase NA Withdrawn
NCT05512260 2026-02-11
BESTa
Karolinska Institutet
Phase NA Withdrawn
NCT07226102 2026-02-04
Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer
City of Hope Medical Center
Phase NA Withdrawn
NCT05850663 2026-02-03
Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer
University of Oklahoma
Phase NA Withdrawn
NCT02554344 2026-01-30
Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs)
Baylor Research Institute
Phase EARLY_PHASE1 Withdrawn
NCT06545617 2026-01-07
A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer
Bio-Thera Solutions
Phase 1/2 Withdrawn
NCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT06866951 2025-12-16
A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial
Women's Hospital School Of Medicine Zhejiang University
Phase 2/3 Withdrawn
NCT05483023 2025-10-14
18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
NCT04053114 2025-08-29
MOLTHYSO
Institut Bergonié
Withdrawn
NCT05341284 2025-08-14
HPV-RWS
Peking University
Withdrawn
NCT06393751 2025-06-03
Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT02446652 2025-05-29
Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer
National Institute of Cancerología
Phase 3 Withdrawn
NCT05672095 2025-05-23
Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT02756130 2025-05-13
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
Jonsson Comprehensive Cancer Center
Phase 1/2 Withdrawn